Global Alzheimer's Disease Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Alzheimer's Disease Biomarkers Market size is expected to reach USD 3.56 Billion in 2034 from USD 1.59 Billion (2025) growing at a CAGR of 9.35% during 2026-2034.

The Global Alzheimer's Disease Biomarkers Market is growing due to the increasing prevalence of Alzheimer's disease and other neurodegenerative disorders. The aging global population is a key factor driving the need for early and accurate diagnosis. Biomarkers play an important role in detecting the disease at an early stage, which helps in better treatment planning and disease management. This rising focus on early diagnosis is supporting market growth.

Research and development activities in neurology are accelerating the discovery of new biomarkers. Technological advancements in imaging techniques, cerebrospinal fluid testing, and blood-based biomarker tests are improving diagnostic accuracy. Government funding and support for dementia research are also contributing to market expansion. Pharmaceutical companies are increasingly relying on biomarkers for drug development and clinical trials.

In the coming years, the market is expected to benefit from the development of non-invasive and cost-effective diagnostic tests. Blood-based biomarkers are likely to gain significant attention due to their convenience. Growing awareness about brain health and increasing investments in personalized medicine will further boost demand. As new therapies for Alzheimer's emerge, biomarker testing will become even more essential.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type Of Biomarker

CSF Biomarkers
Amyloid Beta
Tau Protein
Genetic Biomarkers
Apolipoprotein E
Blood Biomarkers
Others

By Detection Technique

Molecular Diagnostics
Immunoassays

By End-User

Hospitals & Clinics
Diagnostic Laboratories
Research Institutes and Academic Centers
Others

COMPANIES PROFILED

Enzo Life Sciences Inc, Thermo Fisher Scientific Inc, AnaSpec Inc, Merck KGaA, Cell Signaling Technology Inc, Fujirebio, Imagilys, NanoSomiX, QIAGEN, 23andMe Inc, Quanterix, C2N Diagnostics, Quest Diagnostics
We can customise the report as per your requirements.

Product Code: VMR112110501

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY TYPE OF BIOMARKER 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Type Of Biomarker
4.2. CSF Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Amyloid Beta Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Tau Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Genetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Apolipoprotein E Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. Blood Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY DETECTION TECHNIQUE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Detection Technique
5.2. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Immunoassays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY END-USER 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast End-user
6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Research Institutes and Academic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Type Of Biomarker
- 7.2.2 By Detection Technique
- 7.2.3 By End-user
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Type Of Biomarker
- 7.3.2 By Detection Technique
- 7.3.3 By End-user
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Type Of Biomarker
- 7.4.2 By Detection Technique
- 7.4.3 By End-user
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Type Of Biomarker
- 7.5.2 By Detection Technique
- 7.5.3 By End-user
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Type Of Biomarker
- 7.6.2 By Detection Technique
- 7.6.3 By End-user
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ALZHEIMER'S DISEASE BIOMARKERS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Enzo Life Sciences Inc
- 9.2.2 Thermo Fisher Scientific Inc
- 9.2.3 AnaSpec Inc
- 9.2.4 Merck KGaA
- 9.2.5 Cell Signaling Technology Inc
- 9.2.6 Fujirebio
- 9.2.7 Imagilys
- 9.2.8 NanoSomiX
- 9.2.9 QIAGEN
- 9.2.10 23andMe Inc
- 9.2.11 Quanterix
- 9.2.12 C2N Diagnostics
- 9.2.13 Quest Diagnostics